Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

March 05, 2020 00:26:10
Episode Cover

COVID-19 Update - March 2020

In December 2019 a novel coronavirus (now named COVID-19) was identified as responsible for a cluster of pneumonia cases in Wuhan, China. As of...

Listen

Episode 0

July 16, 2021 00:22:20
Episode Cover

The ED-AWARENESS Study

Ventilated ED patients may be at high risk for awareness with paralysis, thereby increasing the risk of long-term psychological sequelae.  In this podcast, we...

Listen

Episode 0

September 17, 2019 00:19:53
Episode Cover

Do ED-Based ICUs Make a Difference?

Over the past decade, the annual hours of critical care delivered in US emergency departments has sharply risen. Undoubtedly, many critically ill patients remain...

Listen